STN: BL 125046
Proper Name: Immune Globulin Intravenous (Human), 10%, Caprylate/Chromatography Purified
Manufacturer: Talecris Biotherapeutics, Inc, License #1716
- For use in primary humoral immunodeficiency and idiopathic thrombocytopenic purpura.
September 23, 2013 Approval Letter - GAMUNEX®-C/GAMMAKED™
Approval Letters for Safety Labeling Changes
October 13, 2010 Approval Letter - Gamunex-C
New route of administration, subcutaneous administration, for the treatment of Primary Humoral Immunodeficiency.
September 12, 2008 Approval Letter - Gamunex-C
Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse.
August 27, 2003 Approval Letter
Indication: Primary humoral immunodeficiency and idiopathic thrombocytopenic purpura.
FDA Approves Treatment for Rare Neurologic Disease[ARCHIVED]
Press Release: September 12, 2008